PhorMed Inc, a Nevada Corporation (“PhorMed” or the “Company”), is a privately held clinical stage biopharmaceutical company. The Company’s study drug RP-323 is in an on-going acute respiratory distress syndrome (ARDS) study. ARDS is a lung disorder where fluid collects in the air sacs of the lungs, depriving organs of oxygen. These studies have generated positive results showing RP-323 significantly reduces the influx of inflammatory cells into the lungs thereby limiting damage to the lungs.
Read More
On March 24, 2020, PhorMed acquired the Anti-Virus and COVID-19 treatment patent rights from Prof. Richard L. Chang. PhorMed plans to research and develop a treatment for COVID-19 using its platform technology, RP-323.
Read More
On January 1, 2020, welcomes Mr. Stuart Greene to PhorMed. He brings fresh ideas and new vision while also bringing many years of professional experience to our team. Mr. Greene will be the department head with the title of Marketing and Business Development Director.
Read More
On November 26, 2019, PhorMed signs with Digital Niche Agency (DNA) for its marketing needs. DNA will be handling all media buying and ad placements. They were chosen for their experience having been actively supporting industry needs from the onset of Equity Crowd Funding.
Read More
On October 31, 2019, PhorMed engaged StartEngine to run its Equity Crowd Funding campaign with the goal of raising up to $1.07 million.
Read More
On September 17, 2019, inventor, Prof. Richard L. Chang, successfully recruited Professor Harold H. Lee to PhorMed’s Scientific Advisory Board. Prof. Lee will advise on the company’s medical writing needs.
Read More
PhorMed is pleased to add three members to its advisory board and is honored to announce Professor Xi Zheng, Professor Renping Zhou, and Sean O’Connell, Ph.D.
Read More
On August 1, 2019, PhorMed entered into multiple contracts to acquire five of Professor Richard L. Chang’s patent inventions.
Read More
